Quince Therapeutics

QNCX

Market cap $17.9M

QNCX Hedge Fund Activity: Q1 2026 in Review

43 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Quince Therapeutics (QNCX) for Q1 2026, worth a combined $1.44M — down 98% from $67.5M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of QNCX and 17 opened new positions — a net loss of 18 holders — while 11 trimmed existing stakes and 8 added.

The largest buyer was Woodline Partners, adding an estimated $3.27M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $8.95M sold.

• 43 institutional investors held Quince Therapeutics (QNCX) as of Q1 2026, down from 62 in Q4 2025.
• Funds reported $1.44M of Quince Therapeutics stock for Q1 2026, down 98% quarter-over-quarter.
• 17 funds opened new Quince Therapeutics positions in Q1 2026 and 35 closed out, a net change of -18 holders.
• The largest Quince Therapeutics buyer in Q1 2026 was Woodline Partners, an estimated $3.27M added.
• The largest Quince Therapeutics seller in Q1 2026 was Nantahala Capital Management, an estimated $8.95M sold.

Based on aggregated 13F filings for Q1 2026.